Georgia vs Morocco: Average cost of drugs for extensively drug-resistant tuberculosis
Georgia
4,500 constant 2022 US$
in 2022
Morocco
4,500 constant 2022 US$
in 2024
Georgia rank
14th
Morocco rank
14th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Georgia
- Morocco
How they compare
Georgia currently reports 4,500 constant 2022 US$ against 4,500 constant 2022 US$ in Morocco, a difference of 0 constant 2022 US$.
The two have swapped places 1 time across 5 shared years of data; in 2018 it was Morocco ahead.
Georgia ranks 14th and Morocco ranks 14th of 56 countries.
Across the 2 decades both report, Georgia averaged higher in 1 and Morocco in 1.
Head to head by decade
| Decade | Georgia | Morocco | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,250 constant 2022 US$ | 7,800 constant 2022 US$ | 2,550 constant 2022 US$ | Morocco |
| 2020s | 4,533 constant 2022 US$ | 3,515 constant 2022 US$ | 1,019 constant 2022 US$ | Georgia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Georgia or Morocco?
- Georgia, at 4,500 constant 2022 US$ against 4,500 constant 2022 US$ in Morocco as of 2022.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Georgia and Morocco?
- 0 constant 2022 US$, with Georgia ahead.
- How many years of comparable data are there for Georgia and Morocco?
- 5 years are reported by both, from 2018 to 2022.
- How do Georgia and Morocco rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Georgia ranks 14th and Morocco ranks 14th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.